Chemoresection may be a minimally invasive option for recurrent Ta, intermediate-risk non-muscle-invasive bladder cancer (NMIBC).
UGN-102 shows a 79.6% complete response rate in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. UGN-102 offers a non-surgical alternative, avoiding cystoscopy and anesthesia, ...
Pain control was achieved by TUF in 70.0 percent of 240 patients; 18 patients underwent cystectomy for intractable pain. (HealthDay News) — For patients with interstitial cystitis (IC), transurethral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results